The findings show that the FAM167A-mediated noncanonical NF-κB pathway is a critical mechanism underlying BCR-ABL-independent TKI resistance in CML. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.